Drugs.com - New Drug Approvals
New drug approvals news from Drugs.com. Comprehensive, up-to-date drug news for consumers and healthcare professionals.
-
FDA Approves Infilbray (venglustat) to Treat Neurological Manifestations of Type 3 Gaucher Disease
Paris, November 18, 2026. The US Food and Drug Administration has approved Infilbray (venglustat), a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, for the treatment of neurological manifestations... -
FDA Approves Livsayis (cemdisiran) for the Treatment of Generalized Myasthenia Gravis
TARRYTOWN, N.Y., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis (cemdisiran) for the treatment of generalized myasthenia gravis... -
FDA Approves Lembaz (adrabetadex) to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C
THOUSAND OAKS, Calif., November 17, 2026 – Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Lembaz... -
FDA Grants Accelerated Approval to Nelkarmi (neladalkib) for Previously-Treated Advanced ALK-Positive Non-Small Cell Lung Cancer
London, UK -- 17 November 2026 -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic... -
Novartis Cosentyx Becomes First and Only FDA-Approved Anti-IL-17 Biologic for People with Polymyalgia Rheumatica
Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response... -
FDA Approves Wilserdly (giredestrant) for ER-Positive, ESR1-Mutated Advanced Breast Cancer
South San Francisco, CA -- November 16, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly (giredestrant) in... -
U.S. FDA Approves Igalmi as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
PARSIPPANY, N.J., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the U.S. Food and Drug Administration (FDA) approval of Igalmi (dexmedetomidine)... -
Cytokinetics Announces Prescribing Information for Myqorzo (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S...